BENRALIZUMAB - Emerging Insight and Market Forecast - 2030

“BENRALIZUMAB- Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the BENRALIZUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

Fasenra (Benralizumab) is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death). Fasenra is AstraZeneca's first respiratory biologic, now approved as an add-on maintenance treatment for severe eosinophilic asthma in the US, EU, Japan and other countries, with further regulatory reviews ongoing. In the US, Fasenra is approved for self-administration in the Fasenra Pen. In the EU, Fasenra is approved for self-administration in either the single-use, pre-filled syringe or the Fasenra Pen. Fasenra was developed by AstraZeneca and is in-licensed from BioWa, Inc., a wholly-owned subsidiary of Kyowa Kirin Co., Ltd., Japan.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around BENRALIZUMAB.
• The report contains forecasted sales for BENRALIZUMAB till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase II) for Chronic Spontaneous Urticaria.
• The report also features the SWOT analysis with analyst insights and key findings of BENRALIZUMAB.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BENRALIZUMAB Analytical Perspective

In-depth BENRALIZUMAB Market Assessment

This report provides a detailed market assessment of BENRALIZUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

BENRALIZUMAB Clinical Assessment

The report provides the clinical trials information of BENRALIZUMAB covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Chronic Spontaneous Urticaria is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence BENRALIZUMAB dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Chronic Spontaneous Urticaria are giving market competition to BENRALIZUMAB and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of BENRALIZUMAB.
• The in-depth analysis of the forecasted sales data of BENRALIZUMAB from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BENRALIZUMAB.

Key Questions Answered

• Which company is developing BENRALIZUMAB along with the phase of the clinical study?
• What is the technology utilized in the development of BENRALIZUMAB?
• What is the product type, route of administration and mechanism of action of BENRALIZUMAB?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BENRALIZUMAB development?
• What are the key designations that have been granted to BENRALIZUMAB?
• What is the forecasted market scenario of BENRALIZUMAB?
• What is the history of BENRALIZUMAB and what is its future?
• What is the forecasted sales of BENRALIZUMAB in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to BENRALIZUMAB?
• Which are the late-stage emerging therapies under development for the treatment of the PPD?